Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-cash Items (2020 - 2023)

Mirum Pharmaceuticals has reported Non-cash Items over the past 4 years, most recently at $48.5 million for Q4 2023.

  • Quarterly results put Non-cash Items at $48.5 million for Q4 2023, down 6.09% from a year ago — trailing twelve months through Dec 2023 was $48.5 million (down 6.09% YoY), and the annual figure for FY2023 was $48.5 million, down 6.09%.
  • Non-cash Items for Q4 2023 was $48.5 million at Mirum Pharmaceuticals, up from $20.0 million in the prior quarter.
  • Over the last five years, Non-cash Items for MIRM hit a ceiling of $55.2 million in Q1 2023 and a floor of $20.0 million in Q3 2023.
  • Median Non-cash Items over the past 4 years was $48.6 million (2020), compared with a mean of $44.6 million.
  • Biggest five-year swings in Non-cash Items: surged 68.69% in 2021 and later crashed 56.33% in 2023.
  • Mirum Pharmaceuticals' Non-cash Items stood at $40.6 million in 2020, then dropped by 19.67% to $32.6 million in 2021, then soared by 58.24% to $51.6 million in 2022, then fell by 6.09% to $48.5 million in 2023.
  • The last three reported values for Non-cash Items were $48.5 million (Q4 2023), $20.0 million (Q3 2023), and $51.4 million (Q2 2023) per Business Quant data.